Argenx
ARGX
#525
Rank
HK$356.48 B
Marketcap
HK$5,761
Share price
-0.91%
Change (1 day)
29.85%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): HK$68.96

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$69.42. In 2024 the company made an earnings per share (EPS) of HK$108.95 an increase over its 2023 EPS that were of -HK$40.39.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$68.96-36.7%
2024HK$108.95-369.77%
2023-HK$40.39-60.46%
2022-HK$102.1463.33%
2021-HK$62.54-40.37%
2020-HK$104.88183.47%
2019-HK$37.00123.09%
2018-HK$16.5854.93%
2017-HK$10.7014.07%
2016-HK$9.3813.05%
2015-HK$8.30-36.34%
2014-HK$13.04209.04%
2013-HK$4.22-33.99%
2012-HK$6.39185.59%
2011-HK$2.24